Various possible indicators for predicting the effectiveness of ICI treatment have been discovered, such as high levels of microsatellite instability/mismatch repair deficiency (MSI-H/dMMR) or high tumor mutation burden (TMB-H), as well as increased expression of PD-L1 in certain tumors.2,3 In a study conducted by Le et al., 53% of patients with dMMR cancers in various tumor types showed a positive response, with a complete response seen in 21% of patients.4 Nevertheless, the occurrence of MSI-H/dMMR is limited in clinical practice. The gene discussed is CD274; the disease is neoplasm.